What happened with AAPG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ascentage Pharma Group International focuses on medicines for blood cancers. Its two marketed drugs are Olverembatinib, approved in China for specified uses in adults with chronic myeloid leukemia, and Lisaftoclax, approved there for previously treated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. It reaches hospitals and pharmacies through its own sales team and third-party distributors. These drug sales provide most of its revenue, and a single customer accounts for most of total revenue.
Innovent shares commercialization of Olverembatinib in designated cities, with Ascentage supplying the products. Innovent also pays for development and commercialization rights through upfront and milestone payments. Takeda has paid for an exclusive option to license Olverembatinib; further license payments and royalties depend on Takeda exercising that option and the agreed conditions being met.
Neither marketed drug is approved outside China, and its other candidates are not yet approved for sale anywhere. Expansion therefore depends on clinical trials and separate regulatory approvals, while current sales depend on treatment uptake and reimbursement. The company has primarily financed its operations through equity funding rather than cash generated by the business.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ascentage’s results hinge on uptake of Olverembatinib and Lisaftoclax in China, with Innovent’s Olverembatinib commercialization and supply partnership a key relationship to watch.
Takeda pays Ascentage for the option to license Olverembatinib while also selling Iclusig, a competing treatment for chronic myeloid leukemia (CML). Watch whether Takeda exercises that option: its licensing income boosted Ascentage’s 2024 revenue, and the absence of that income was the main reason revenue fell in 2025 despite higher drug sales.
BeOne Medicines’ sonrotoclax competes with Ascentage’s Lisaftoclax in treating chronic lymphocytic leukemia (CLL) by targeting BCL2, alongside BeOne’s established BRUKINSA blood-cancer business. Watch sonrotoclax’s clinical progress across previously untreated and relapsed CLL, where BeOne is building both continuous-use and fixed-duration treatment regimens.
AbbVie’s venetoclax competes with Ascentage’s Lisaftoclax for blood-cancer treatment, including chronic lymphocytic leukemia (CLL); both drugs target BCL2.
Enliven Therapeutics, Inc. is developing chronic myeloid leukemia (CML) drugs that compete with Ascentage’s Olverembatinib, rather than running a mature drug-sales business. Its clinical results on effectiveness, safety and ease of use are the news to watch for changes in Olverembatinib’s competitive position.
Novartis sells Scemblix, Tasigna and Gleevec for chronic myeloid leukemia (CML), competing for treatment use with Ascentage’s Olverembatinib. Watch clinical and approval news for these drugs, particularly evidence on effectiveness, safety and patient convenience that could change treatment choices.
AstraZeneca’s Calquence and Ascentage’s Lisaftoclax both address chronic lymphocytic leukemia (CLL), so their clinical results matter for which treatment patients receive first and which drugs are used together.
HUTCHMED and Ascentage both sell internally developed cancer medicines in China, where national reimbursement coverage and sales execution shape uptake and pricing. Watch HUTCHMED’s Elunate sales after its third-line colorectal-cancer coverage was renewed from January 2026 at the 2024–25 reimbursement price—a concrete comparison for Ascentage’s growth after Olverembatinib gained reimbursement coverage.
Novartis AG earningsNVS
Novartis’s report will show whether its chronic myeloid leukemia drugs can keep winning treatment use from Ascentage’s Olverembatinib on effectiveness, safety, or ease of use.
Look for clinical and approval updates on Novartis’s chronic myeloid leukemia drugs, especially evidence on effectiveness, safety, and convenience. Stronger evidence gives patients and doctors more reason to use those established treatments, making it harder for Olverembatinib to win treatment use; weaker evidence may leave it more room, subject to its own clinical results, approval, and availability.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report may show whether it advances its option to license Olverembatinib, a potential source of licensing income for Ascentage beyond sales of its drugs in China.
Look for Takeda to exercise or advance its option to license Olverembatinib, and for any related milestone payment. Licensing progress or payment could add revenue for Ascentage beyond sales of Olverembatinib and Lisaftoclax; without it, China drug sales remain more central to the business. Takeda also sells a chronic myeloid leukemia treatment, but its sales do not directly show how Ascentage’s products are selling.
ABBVIE INC. earningsABBV
AbbVie’s report and related clinical updates can show how venetoclax’s position in chronic lymphocytic leukemia treatment shapes the room for Ascentage’s Lisaftoclax.
Watch for clinical or commercial developments in AbbVie’s venetoclax for chronic lymphocytic leukemia. Stronger evidence or a firmer market position could lead doctors and patients to favor this BCL2-targeting drug, making treatment use harder for Lisaftoclax to win; a weaker position may leave more room, but Lisaftoclax still has to establish its own clinical results, approval, and patient acceptance.
AstraZeneca PLC earningsAZN
AstraZeneca’s report and clinical updates can show how Calquence’s role in chronic lymphocytic leukemia affects Lisaftoclax’s chance to win use alone or in combination.
Watch clinical evidence on Calquence in chronic lymphocytic leukemia, especially its progress as an initial treatment or combination partner. Stronger evidence may lead doctors to use Calquence regimens more often, leaving Lisaftoclax less room to win use alone or alongside another drug; weaker evidence may leave treatment choices more open, subject to Lisaftoclax’s own trial and approval results.
BeOne Medicines Ltd. earningsONC
BeOne Medicines’ report and clinical updates can show whether sonrotoclax’s progress in chronic lymphocytic leukemia is bringing a stronger competitor for Lisaftoclax.
Watch sonrotoclax’s clinical progress in untreated and relapsed chronic lymphocytic leukemia, and how BeOne advances different treatment regimens. Strong trial progress across more patient groups would create more direct competition for Lisaftoclax’s future patient use and place in treatment; weaker or delayed progress would mean less competitive pressure for now, not proof that Lisaftoclax has established efficacy or sales.
Enliven Therapeutics, Inc. earningsELVN
Enliven Therapeutics, Inc.’s report and clinical updates can show whether its chronic myeloid leukemia candidates are becoming stronger competitors to Olverembatinib.
Look for clinical evidence on Enliven’s chronic myeloid leukemia candidates, especially effectiveness, safety, and convenience. Stronger evidence could give doctors and patients another future option and raise the competitive bar for Olverembatinib; weaker evidence means less added competitive pressure for now, but does not prove Olverembatinib’s own benefit or market position.
